Drugs by condition
Drugs approved for iga nephropathy
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
7
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
6
New molecular entities and new biologics
In development
31
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for iga nephropathy.
- Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc. NovelPriority reviewJul 7, 2026
- Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTD NovelBreakthrough therapyAccelerated approvalPriority reviewNov 25, 2025
- Vanrafia (Atrasentan Hydrochloride) · Novartis NovelAccelerated approvalApr 2, 2025
- Fabhalta (Iptacopan Hydrochloride) · Novartis NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 5, 2023
- Filspari (Sparsentan) · Travere NovelAccelerated approvalPriority reviewOrphanFeb 17, 2023
All approved drugs for iga nephropathy, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for iga nephropathy
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- BHV-1400Phase 31 trial
Biohaven Therapeutics Ltd. · IgA Nephropathy
- matched to PovetaciceptPhase 31 trial
Alpine Immune Sciences Inc, A Subsidiary of Vertex · Immunoglobulin A Nephropathy
- SC0062Phase 31 trial
Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)
- SefaxersenRO7434656Phase 31 trial
Roche (Genentech) · Primary IgA Nephropathy
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
- HSK39297 200mgQDPhase 23 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
- HSK39297 300mgQDPhase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
More on iga nephropathy: recruiting trials · published research
Related in kidney and urology: Chronic kidney disease · Overactive bladder · Enlarged prostate (BPH) · Erectile dysfunction
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.